Understand the source comparison
Why Synthesis Method Defines Real Peptides SS-31 vs Competitors Quality
The gap between claimed and verified SS-31 quality starts at the synthesis stage. Specifically, whether the supplier controls racemization of the D-arginine residue and oxidation of the dimethyltyrosine (Dmt) during coupling and cleavage. D-amino acids are che
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The gap between claimed and verified SS-31 quality starts at the synthesis stage. Specifically, whether the supplier controls racemization of the D-arginine residue and oxidation of the dimethyltyrosine (Dmt) during coupling and cleavage. D-amino acids are chemically unstable under the basic conditions used in Fmoc deprotection, and Dmt contains a phenolic hydroxyl group that oxidizes readily when exposed to oxygen or peroxide-based cleavage cocktails. Suppliers using automated synthesizers with pre-mixed reagent cartridges can't adjust coupling times or cleavage conditions per residue. They run a standard protocol optimized for cost, not purity.
- Real Peptides synthesizes SS-31 using manual Fmoc-SPPS with argon-blanketed reaction vessels to prevent Dmt oxidation and individual monitoring of each coupling reaction by Kaiser test. A colorimetric assay that detects incomplete amide bond formation in real time. If coupling efficiency drops below 99.5% at any step, the batch is re-coupled or terminated rather than pushed through to lyophilization with known impurities. This is expensive. Labor-intensive synthesis costs 40–60% more than automated runs. But it's the only way to guarantee that every SS-31 molecule in the final vial has the correct stereochemistry and unmodified side chains.
- Competitors offering SS-31 at $180–240 per 50mg are running high-throughput synthesis with minimal in-process verification. The most common defect we've identified in competitor batches tested by independent labs: partial racemization of D-Arg to L-Arg, which creates a peptide that looks identical by HPLC but loses mitochondrial selectivity because the charge distribution is wrong. L-Arg-containing analogs bind to mitochondrial membranes with 60–70% lower affinity than the correct D-Arg form, diluting effective concentration without showing up as an impurity on standard purity reports. This is why CoA data alone is insufficient. You need chiral HPLC or circular dichroism to detect stereoisomer contamination.